Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma

被引：0
|
作者：
Yu, Jiayi
Kong, Yan
Chi, Zhihong
Tang, Bixia
Sheng, Xinan
Si, Lu
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9588
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Yu, Jiayi
    Yan, Junya
    Guo, Qian
    Chi, Zhihong
    Tang, Bixia
    Zheng, Bin
    Yu, Jinyu
    Yin, Ting
    Cheng, Zhiyuan
    Wu, Xiaowen
    Yu, Huan
    Dai, Jie
    Sheng, Xinan
    Si, Lu
    Cui, Chuanliang
    Bai, Xue
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqia
    Li, Siming
    Zhou, Li
    Flaherty, Keith T.
    Guo, Jun
    Kong, Yan
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6511 - 6523
  • [2] Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
    Kong, Yan
    Sheng, Xinan
    Wu, Xiaowen
    Yan, Junya
    Ma, Meng
    Yu, Jiayi
    Si, Lu
    Chi, Zhihong
    Cui, Chuanliang
    Dai, Jie
    Li, Yiqian
    Yu, Huan
    Xu, Tianxiao
    Tang, Huan
    Tang, Bixia
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqiao
    Li, Siming
    Guo, Jun
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6946 - 6957
  • [3] Prevalent aberrations of CDK4 pathway in acral melanoma and implications for targeted therapy.
    Kong, Yan
    Sheng, Xinan
    Wu, Xiaowen
    Si, Lu
    Ma, Meng
    Yu, Jiayi
    Chi, Zhihong
    Cui, Chuanliang
    Dai, Jie
    Li, Yiqian
    Yan, Junya
    Yu, Huan
    Xu, Tianxiao
    Tang, Huan
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.
    Mao, Lili
    Cao, Yabing
    Sheng, Xinan
    Bai, Xue
    Chi, Zhihong
    Cui, Chuanliang
    Wang, Xuan
    Tang, Bixia
    Lian, Bin
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Li, Caili
    Qi, Zhong Hui
    Si, Lu
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Resistance to PD-1 blockade in melanoma
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (09): : E376 - E376
  • [6] PD-1 blockade in Japanese patients with acral lentiginous melanoma
    Shoushtari, A. N.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1106 - 1108
  • [7] Response and resistance PD-1 pathway blockade
    Topalian, Suzanne L.
    CANCER RESEARCH, 2015, 75
  • [8] Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
    Zaretsky, Jesse M.
    Garcia-Diaz, Angel
    Shin, Daniel S.
    Escuin-Ordinas, Helena
    Hugo, Willy
    Hu-Lieskovan, Siwen
    Torrejon, Davis Y.
    Abril-Rodriguez, Gabriel
    Sandoval, Salemiz
    Barthly, Lucas
    Saco, Justin
    Moreno, Blanca Homet
    Mezzadra, Riccardo
    Chmielowski, Bartosz
    Ruchalski, Kathleen
    Shintaku, I. Peter
    Sanchez, Phillip J.
    Puig-Saus, Cristina
    Cherry, Grace
    Seja, N. P. Elizabeth
    Kong, Xiangju
    Pang, Jia
    Berent-Maoz, Beata
    Comin-Anduix, Begona
    Graeber, Thomas G.
    Tumeh, Paul C.
    Schumacher, Ton N. M.
    Lo, Roger S.
    Ribas, Antoni
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (09): : 819 - 829
  • [9] Genomic alterations of the CDK4-pathway in melanoma and evaluation of the CDK4 Inhibitor PD-0332991
    Sheppard, Karen E.
    Foo, Allen
    Young, Richard
    Waldeck, Kelly
    Pearson, Richard
    McArthur, Grant
    Christensen, James
    CANCER RESEARCH, 2013, 73 (08)
  • [10] PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
    Ali, Lestat R.
    Garrido-Castro, Ana C.
    Lenehan, Patrick J.
    Bollenrucher, Naima
    Stump, Courtney T.
    Dougan, Michael
    Goel, Shom
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    Dougan, Stephanie K.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 220 (04):
12345